key: cord-0034621-whfyqwtl
authors: Leach, Richard
title: Pneumonia
date: 2009
journal: Respiratory Disease and its Management
DOI: 10.1007/978-1-84882-095-1_5
sha: 56428897a3d03c09a12a9aa786eb034363fd4c19
doc_id: 34621
cord_uid: whfyqwtl

Despite antibiotic therapy, pneumonia remains a significant worldwide cause of morbidity and mortality. The term pneumonia covers several distinct clinical entities, and correct classification is vital as the aetiology, infective organism, antibiotic management and outcome are determined by how and where pneumonia was contracted. Early recog-nition and appropriate treatment improve outcome. Critical care physicians must be familiar with all aspects of pneumonia, as they will be expected to advise on and manage severe community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and opportunistic pneumonias in immuno-compromised patients in the wards, high depend-ency units (HDUs) and intensive care units (ICUs). Differences in the recently published antibiotic guidelines between the British and American Tho-racic Societies are highlighted in this chapter.

Pneumonia describes an acute lower respiratory tract (LRT) illness, usually but not always due to infection, associated with fever, focal chest symptoms (with or without clinical signs) and new shadowing on chest radiography ( Figure 5 .1). The many infective micro-organisms and pathological insults that cause pneumonia are listed in Table 5 .1.

In the clinical situation, microbiological classifi cation of pneumonia is not practical, since identifi cation of the organism, even when possible, may take several days. Likewise, anatomical (radiographic) appearance (e.g. lobar pneumonia, which describes consolidation localised to one lobe; or bronchopneumonia, which describes widespread, patchy consolidation) gives little practical information about the cause, course or prognosis of the infection. The following classifi cation is widely accepted:

• Community-acquired pneumonia (CAP) describes LRT infections occurring within 48 h of hospital admission in patients who have not been hospitalised for more than 14 days. The most likely infective organisms are Streptococcus pneumoniae (20-75%), Mycoplasma pneumoniae and Chlamydia pneumoniae.

• Hospital-acquired (nosocomial) pneumonia (HAP) is defi ned as any LRT infection developing greater than 48 h after hospital admission, which was not incubating at the time of admission. HAP includes: (i) ventilator-associated pneumonia (VAP), which refers to pneumonia developing greater than 48-72 h after endotracheal intubation; and (ii) health-care-associated pneumonia (HCAP), which includes any patient admitted to hospital for more than 2 days within 90 days of the infection, residing in a nursing home, receiving therapy (e.g. wound care, intravenous [iv] therapy) within 30 days of the current infection, or attending a hospital or haemodialysis clinic. Likely, causative organisms differ from CAP and include Gram-negative bacilli (∼70%) or Staphylococcus (∼15%).

• Aspiration/anaerobic pneumonia occurs due to bacteroides and other anaerobic infections, which follow aspiration of oropharyngeal contents due 5 Pneumonia Richard Leach to impaired laryngeal competence (e.g. cerebrovascular accident [CVA]) or reduced consciousness (e.g. drugs, alcohol, postoperative).

• Opportunistic pneumonia occurs in immunosuppressed patients taking high-dose steroids, chemotherapy or who are HIV positive. They are susceptible to viral, fungal and mycobacterial infections, in addition to the normal range of bacterial organisms.

• Recurrent pneumonia occurs due to aerobic and anaerobic organisms in cystic fi brosis and bronchiectasis.

Prospective population studies report an annual CAP incidence of 5-11 cases per 1,000 adults and ∼15-45% require hospitalisation (1-4 cases per 1,000) of whom 5-10% are treated in ICU. Incidence is highest in the very young and elderly (∼35 per 1,000 in patients aged >75 years). Mortality is <1% in patients treated at home, 5-12% in hospitalised patients and 25-50% in ICU patients. Seasonal variation occurs with individual pathogens; M. pneumonia, Staphylococcus and infl uenza virus occur in winter, Legionella spp. in September-October and Coxiella burnetii in spring. Annual cycles are also reported (e.g. 4 yearly mycoplasma epidemics). Frequent viral infections increase CAP in winter.

Identifying the causative pathogen in CAP is difficult and results vary with methodology (e.g. bacterial quantifi cation), geography (e.g. the UK, Europe, the USA) and illness severity (e.g. community, hospital or ICU). No infective cause is found in 30-50% of cases, but in virtually all studies the most frequently identifi ed organism is S. pneumoniae (20-75%). The 'atypical' bacterial pathogens including M. pneumonaie, Chlamydia pneumoniae and Legionalla spp. (2-25%) and viral infections including infl uenza A and B (8-12%) are relatively common causes of CAP. Haemophilus infl uenza and Moraxella catarrhalis are often associated with COPD exacerbations and staphylococcal infection may follow infl uenza. Respiratory syncytial virus affects children <2 years old. Alcoholic, diabetic, heart failure and nursing-home patients are prone to infection with staphylococcal, anaerobic and Gramnegative organisms. Table 5 .2 lists factors associated with increased risk of CAP. Specific risk factors include age (e.g. mycoplasma in young adults), occupation (e.g. brucellosis in abattoir workers, C. burnetii [Q fever] in sheep workers), environment (e.g. psittacosis with pet birds, tularaemia and erlichiosis due to tick bites) or geographical (e.g. coccidomycosis in southwest USA). Epidemics of C. burnetti (Q fever) or Legionella pneumophila are often localised. For example, patients developing Legionnaires disease may have been exposed to a contaminated air conditioner at a specifi c hotel.

Diagnosis of CAP on the basis of history and clinical fi ndings is inaccurate without a chest radiograph, and several studies have demonstrated that the causative organism cannot be predicted from clinical features. In particular, 'atypical' pathogens do not have a characteristic clinical presentation. The diagnostic aims are to (1) establish the diagnosis of pneumonia, (2) determine classifi cation (aetiology), which aids initial antibiotic choice, (3) assess severity, which determines the most appropriate ward placement (e.g. ward, HDU or ICU), (4) adjust antibiotic therapy when microbiological results are available, and (5) identify and treat complications.

• Clinical features: symptoms may be general (e.g. malaise, fever, rigors, myalgia) or chest-specifi c (e.g. dyspnoea, pleurisy, cough, discoloured sputum, haemoptysis). Signs include cyanosis, tachycardia and tachypnoea; with focal dullness, crepitations, bronchial breathing and pleuritic rub on chest examination. In young or old patients and in those with atypical pneumonias (e.g. mycoplasma, legionella) non-respiratory features (e.g. headache, confusion, rashes, diarrhoea) may predominate. Complications are shown in Figure 5 .3.

• Investigations: routine blood tests should be included. White cell count (WCC) and C-reactive protein (CRP) confi rm infection, abnormal liver function tests suggest Legionella spp. or M. pneumoniae infection and haemolysis and cold agglutinins occur in ∼50% of mycoplasma infections. Blood gases: are performed to identify respiratory failure. Microbiology: is essential in all cases but no micro-organism is isolated in ∼33-50% of patients due to previous antibiotic therapy or inadequate specimen collection. Blood cultures are recommended in severe pneumonia and may be positive in ∼25%. Sputum, pleural fl uid and bronchoalveolar lavage samples, with appropriate staining (e.g. Gram stain), culture and assessment of antibiotic sensitivity may determine the pathogen (∼30-50%) and effective therapy. Serology: identifi es M. pneumoniae infection, but long processing times limit clinical value. Recently developed rapid antigen detection tests for Legionella spp. (e.g. in urine) and S. pneumoniae (e.g. in serum, pleural fl uid, urine) are more useful. Radiological: chest x-ray (CXR) and computed tomography (CT) scans aid diagnosis, monitor deterioration, indicate severity and aid early detection of complica tions ( Figure 5 .3). Resolution of radio logical changes may be slow and should not lead to further investigation during clinical improvement.

• Severity assessment: the following features are associated with increased CAP mortality and indicate the need for monitoring on an HDU/ ICU. (a) Clinical: age > 60 years, respiratory rate > 30/min, diastolic blood pressure < 60 mmHg, new atrial fi brillation, confusion, multilobar involvement and coexisting illness. (b) Laboratory: urea > 7 mmol/L, albumin < 35 g/L, hypoxaemia PO 2 < 8 kPa, leucopenia (WCC < 4 × 10 9 /L), leucocytosis (WCC > 20 × 10 9 /L) and bacteraemia. Severity scoring: the recently validated CURB-65 score, which allocates one points for each of confusion; urea > 7 mmol/L; respiratory rate > 30/min; low systolic (<90 mmHg) or diastolic (<60 mmHg) blood pressure and age > 65 years, stratifi es patients into mortality groups suitable for different management pathways. A score greater than 4 indicates the need for admission to a monitored bed in an HDU or ICU.

These include oxygen to maintain PaO 2 > 8 kPa (SaO 2 > 90%) and intravenous (iv) fl uid and if necessary inotropic support to maintain a mean blood pressure > 65 mmHg and urine output 0.5-1 mL/kg/min. Ventilatory support: non-invasive (e.g. CPAP, NIPPV) or mechanical ventilation (MV) may be required in respiratory failure. Persisting hypoxia with PaO 2 < 8 kPa despite maximal oxygen administration, progressive hypercapnia, severe acidosis (pH < 7.2), shock and depressed consciousness are indications for mechanical ventilation. Alveolar recruitment strategies using PEEP aid oxygenation and ventilator modes that avoid high peak pressures and alveolar hyperinfl ation are optimal. Physiotherapy and bronchoscopy may aid sputum clearance and sample collection for further microbiology. Steroids do not improve pneumonia resolution, but may be indicted (hydrocortisone 8 mg/h) in patients with septic shock who are poorly responsive to fl uid and inotropic therapy.

Initial antibiotic therapy represents the 'best guess', according to pneumonia classifi cation and likely organisms, as microbiological results are often not available for >24 h. Therapy is adjusted when results and antibiotic sensitivities are available. The American and British Thoracic Societies (ATS, BTS) recommendations for initial antibiotic therapy differ slightly and are as follows:

• Non-hospitalised patients: with less severe symptoms usually respond to oral monotherapy with amoxicillin 0.5-1 g tds (BTS), or a macrolide (e.g. clarithromycin 500 mg bd) (ATS/BTS) or doxycycline 100 mg od (ATS). Patients with severe symptoms or at risk for drug-resistant S. pneumoniae (e.g. recent antibiotics, comorbidity, alcoholism, immunosuppressive illness, recent travel to areas with high levels of S. pneumoniae resistance [e.g. Portugal, Spain]) are treated with a β-lactam (e.g. co-amoxiclav 625 mg tds) plus a macrolide or doxycycline; or an oral antipneumococcal fl uoroquinolone alone (e.g. levofl oxacin 500 mg od, moxifl oxacin) (ATS).

• Hospitalised patients: antibiotic therapy must cover 'atypical' organisms and S. pneumoniae at admission. If not severe, the BTS suggests that combined ampicillin plus macrolide (oral or iv) may be adequate. In severe CAP, the BTS recommends intravenous therapy with co-amoxiclav 1.2 g tds or a second-or third-generation cephalosporin (e.g. cefuroxime 1.5 g tds iv) plus a macrolide (e.g. clarithromycin 500 mg bd). The ATS guidelines recommend intravenous therapy with a β-lactam (e.g. ceftriaxone 1-2 g od) plus an advanced macrolide (clarithromycin 500 mg bd) or an antipneumoccocal fl uoroquinolone (e.g. levofl oxacin 500 mg bd or moxafl oxacin). Staphylococcal infection following infl uenza and H. infl uenzae in COPD should also be appropriately covered. An antipseudomonal agent may be required when there is underlying structural lung disease.

Hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) and health-care associated pneumonia (HCAP) affects 0.5-2% of hospitalised patients. Pathogenesis, causative organisms and outcome differ from community-acquired pneumonia (CAP). Preventative measures and early antibiotic therapy guided by awareness of the role of potential multidrugresistant (MDR) pathogens improve outcome ( Epidemiology HAP is the second commonest nosocomial (hospital-acquired) infection in the USA (after wound infection) and the most important in terms of mortality. Available data suggest that it affects between 5 and 10 per 1,000 hospital admissions lengthens hospital stay by 3-14 days/patient. Incidence is highest in surgical and ICU wards and in teaching hospitals. In ICU, HAP accounts for 25% of all infections and ∼50% of prescribed antibiotics. The risk of HAP increases 6-20-fold during mechanical ventilation (MV) and occurs in 9-27% of intubated patients. VAP accounts for >80% of all HAPs. The risk of VAP is highest early in the course of hospital stay and is estimated to be 3%/day during the fi rst 5 days of MV, 2%/day during days 5-10 of MV and 1%/day after this. As most MV is short term about 50% of all episodes of VAP occur during the fi rst 4 days of MV.

HAP is caused by a wide spectrum of bacterial pathogens. Time of onset (i.e. early or late-onset HAP/VAP) and risk factors for infection with MDR organisms determine potential pathogens (Table 5. 3). Aerobic Gram-negative bacilli (e.g. Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter spp.) cause ∼60-70% of infections and Staphylococcus aureus causes ∼10-15%. S. pneumoniae and H. infl uenzae may be isolated in early onset HAP/VAP. In ICU, >50% S. aureus infections are methicillin-resistant (MRSA). In general, the bacteriology in nonventilated and ventilated patients is similar. Pneumonia due to S. aureus is more common in diabetics, head trauma and ICU patients. Reported rates of polymicrobial infections vary widely but are increasing and are especially high in patients with ARDS. Viral and fungal infections are rare in immunocompetent hosts.

Oropharyneal colonisation with enteric Gramnegative bacteria occurs in most hospitalised patients within a few days of admission due to immobility, impaired consciousness, instrumentation (e.g. nasogastric tubes, gastroscopy), inadequate attendant hygiene with cross infection or inhibition of gastric acid secretion (e.g. proton pump inhibitor therapy) ( Figure 5.2) . Subsequent aspiration of nasopharyngeal secretions (or gastric contents) due to supine positioning, reduced consciousness, diffi culty swallowing, leakage past endotracheal-tube cuffs, infected biofilm in the endotracheal tube with subsequent embolisation to distal airways or direct inoculation of the airways during suctioning introduces these organisms into the LRT. Impaired mechanical, cellular and humoral host defences and inability to clear secretions (e.g. structural lung disease, sedation, MV, postoperative pain) promote ensuing infection. Haematogenous spread from distant infected sites (e.g. infected central lines) may also cause HAP. 

Early diagnosis and treatment of HAP improves morbidity and mortality and requires constant vigilance in hospital patients. Antibiotic therapy must not be delayed while awaiting diagnostic tests and microbiological results. 

Supportive therapy includes supplemental oxygen to maintain PaO 2 > 8 kPa (saturation > 90%) and intravenous fl uids (± vasopressors or inotropes) to maintain a mean blood pressure >65 mmHg and urine output 0.5-1 mL/kg/min. Ventilatory support including non-invasive (e.g. CPAP, NIPPV) or mechanical ventilation may be required in respiratory failure (see CAP management). Intensive insulin therapy to maintain serum glucose levels between 4 and 6.5 mmol/L improves outcome. Vigorous physiotherapy and adequate analgesia aid sputum clearance postoperatively and in the immobilised patient. Avoid heavy sedation and paralytic agents that may depress cough. Semirecumbent nursing of bed-bound patients with elevation of the bedhead to 30° reduces aspiration risk. Continuous subglottic aspiration using specially designed endotracheal tubes may reduce early onset VAP but frequency of ventilator circuit changes does not affect VAP incidence. Stress ulcer prophylaxis with either sucrulfate or proton pump inhibitors is acceptable although there is a trend to reduce VAP with sucrulfate. It is essential that modifi able risk factors are addressed (Table 5. 

Antibiotic therapy is empirical (as with CAP) while awaiting microbiological guidance. However, the causative organisms and suitable antibiotics differ from CAP. The initial key decisions are (i) whether the patient has risk factors for MDR organisms (Table 5. 3), and (ii) whether the patient has early or late-onset HAP/VAP or HCAP, which determines the need for broad-spectrum (i.e. combination) antibiotic therapy. Figure 5 .4 illustrates the recently published American Thoracic Society guidelines for initial, empiric antibiotic therapy. Initial therapy should be intravenous in all patients. About 50% of the initial, empiric treatment regimes will need modifi cation due to either resistant organisms or failure to respond. However, it is important to try and get the antibiotic treatment 'right the fi rst time' because mortality is lower in patients receiving effective initial antibiotic therapy compared to those that require a treatment change. Consequently, local patterns of bacterial infection and antibiotic resistance should be used to establish the 'best empiric therapy regimen' for an individual hospital.

• In early onset HAP/VAP (<4 days in hospital) with no risk factors for MDR organisms, antibiotic monotherapy is advised with:

○ A β-lactam/β-lactamase inhibitor (e.g. piperacillin-tazobactam 4.5 g qds iv) ○ A third-generation cephalosporin (e.g. ceftazidime 2 g tds iv) or ○ A fl oroquinolone (e.g. ciprofl oxacin 400 mg tds iv) • In late-onset HAP/VAP (>4 days in hospital) or with risk factors for MDR pathogens (Table 5 .4) and most HCAP combination therapy, with broad-spectrum antibiotics that cover MDR Gram-negative bacilli and MRSA, may be required. For example:

○ An antipseudomonal cephalosporin (e.g. ceftazidine 2 g tds iv), an antipseudomonal carbepenem (e.g. imipenem 0.5-1 g qds, meropenem 1 g tds iv), or a β-lactam/β-lactamase inhibitor (e.g. piperacillin-tazobactam 4.5 g qds iv). ○ Plus an antipseudomonal fl uoroquinolone (e.g. ciprofl oxacin 400 mg tds iv, levofl oxacin 750 mg od iv) or aminoglycoside (e.g. gentamicin 7 mg/kg od iv, adjusted to maintain monitored trough levels <1 μg/mL 

The crude mortality rate for HAP may be as high as 30-70%, but many of these critically ill patients die of their underlying disease rather than pneumonia. The directly 'attributable mortality' due to HAP is estimated to be 33-50% in case-matched VAP studies. Delayed or ineffective antibiotic therapy, bacteraemia (especially with P. aeruginosa or Acinetobacter spp.), medical rather than surgical illness and VAP also increase mortality.

Early onset HAP/VAP (defi ned as occurring within the fi rst 4 days of hospitalisation) is usually caused by antibiotic-sensitive bacteria and carries a better prognosis than late-onset HAP/VAP (defi ned as occurring 5 days or more after hospitalisation), which is associated with MDR pathogens. However, in early onset HAP/VAP, prior antibiotic therapy or hospitalisation predisposes to MDR pathogens and is treated as late-onset HAP/VAP.

Bacteroides and other anaerobic infections follow aspiration of oropharyngeal contents due to impaired laryngeal competence (e.g. CVA) or reduced consciousness (e.g. drugs, alcohol) ( Figure 5 .5). Lung abscesses are common. Antibiotic therapy should include anaerobic coverage (e.g. metronidazole 500 mg tds iv). Large lung abscesses may require oral antibiotic therapy for several weeks.

HIV, bone marrow transplant and chemotherapy patients are susceptible to viral (e.g. cytomegalovirus), fungal (e.g. aspergillus) and mycobacterial infections, in addition to the normal range of organisms. Severely immunocompromised patients require isolation, barrier nursing and combined broad-spectrum antibiotic, antifungal (e.g. ampho tericin) and antiviral (e.g. acyclovir) regimes. HIV patients with CD 4 counts <200/mm 3 are at high risk of opportunistic infections including Pneumocystis carinii pneumonia (PCP), toxoplasmosis and mycobacterium avian intracellulare. PCP is treated with steroids and high-dose co-trimoxazole.

Recurrent pneumonia with aerobic and anaerobic organisms occurs in cystic fi brosis and bronchiectasis. Pulmonary fi brosis with distorted architecture and frequent antibiotic usage result in MDR organisms and the need for broad-spectrum regimens adjusted according to microbiological results and antibiotic sensitivities.

BTS Guidelines for the management of community acquired pneumonia in adults

Guidelines for the management of adults with community-acquired pneumonia; diagnosis, assessment of severity, microbial therapy and prevention

BTS Guidelines for the management of community acquired pneumonia in adults -2004 update

Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia

Hospitalacquired pneumonia

Aspiration pneumonia; chest x-ray (CXR) 6 h after aspiration of gastric contents